What is Gyre Therapeutics Inc. (GYRE) stock price today?

Gyre Therapeutics Inc. (GYRE) currently trades at $7.68 per share. The stock has a market capitalization of $696.73M and a P/E ratio of 381.50x.

Is GYRE stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Gyre Therapeutics Inc. has a Smart Value Score of 39/100 (Grade D), resulting in a "Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is the GYRE stock price target for 2026?

WallStSmart's 12-month price target for Gyre Therapeutics Inc. is $0.94.

What is Gyre Therapeutics Inc.'s revenue and earnings?

Gyre Therapeutics Inc. has trailing twelve-month (TTM) revenue of $116.59M with profit margins of 4.31%. Earnings per share (EPS) is $0.02.

GYRE

Gyre Therapeutics Inc.

NASDAQ: GYRE · HEALTHCARE · BIOTECHNOLOGY

$7.68

+4.49% today

Updated 2026-04-30

Market cap

$696.73M

P/E ratio

381.50

P/S ratio

5.98x

EPS (TTM)

$0.02

Dividend yield

—

52W range

$7 – $12

Volume

0.1M

Market cap

$696.73M

P/E ratio

381.50

P/S ratio

5.98x

EPS (TTM)

$0.02

Dividend yield

—

52W range

$7 – $12

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: D

Sell

Investment rating

8.0

Growth

5.0

Quality

C+

5.0

Profitability

C+

4.0

Valuation

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$18.67

+143.10%

12-Month target

$0.94

-87.76%

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 33.40% QoQ

Risks

- Thin margins at 4.31%

- Negative free cash flow $-5.77M

- P/E 381.50x — expensive valuation

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$102.29M	$113.45M	$105.76M	$116.59M	$116.59M
Net income	$2.30M	$-92.93M	$12.09M	$5.03M	$-1.72M
EPS	—	—	—	—	$0.02
Free cash flow	$5.68M	$17.31M	$-6.77M	$-180000.00	$-5.77M
Profit margin	2.25%	-81.92%	11.43%	4.31%	4.31%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
GYRE	$696.73M	39	8.0	5.0	4.0	5.0	—	Hold
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Gyre Therapeutics Inc. trades at $7.68. representing a P/E of 381.50x trailing earnings. Our Smart Value Score of 39/100 indicates the stock is weak. TTM revenue stands at $116.59M. with profit margins at 4.31%.

Frequently asked questions

What is Gyre Therapeutics Inc.'s stock price?

Gyre Therapeutics Inc. (GYRE) trades at $7.68.

Is Gyre Therapeutics Inc. overvalued?

Smart Value Score 39/100 (Grade D, Sell).

What is the price target of Gyre Therapeutics Inc. (GYRE)?

The analyst target price is $18.67, representing +143.1% upside from the current price of $7.68.

What is Gyre Therapeutics Inc.'s revenue?

TTM revenue is $116.59M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio5.98x

ROE8.21%

Beta6.40

50D MA$7.68

200D MA$7.67

Shares out0.09B

Float0.02B

Short ratio—

Avg volume0.1M

Performance

1 week+3.09%

1 month+10.04%

3 months-6.58%

YTD+8.64%

1 year—

3 years—

5 years—

Compare

GYRE vs LLY →GYRE vs JNJ →GYRE vs ABBV →Stock screener →